Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma

Abstract

Travoprost was well tolerated and significantly reduced IOP in NTG patients. In addition, initial IOP reductions were maintained throughout follow-up. Travoprost was found to be more effective in patients with greater baseline IOP.

Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma

“…These percentages are much higher than that observed in our study; however, our patients had relatively low baseline IOPs. In fact, it has also been reported that travoprost reduced the IOP in eyes with NTG by 16.1% to 20.2% of the baseline IOP [27][28][29], which is quite comparable to our findings. There is evidence that the CCT can affect the values of the IOP measured by an applanation tonometer, and formulas have been presented which can convert the measured IOP to the real IOP taking into account the CCT [26,30,31].…”

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma

“…10,13,20,21 Travoprost 0.004% has been reported to have similar results (16.7% to 25.1%). 17,18 Our results are in accordance with the results of these previous studies.…”

“…18 Achievement of an IOP reduction greater than 30% as recommended by the CNTG study group is very difficult using a single, topical antiglaucoma eye drop. [10][11][12][13]17,18,20,21 In our study, the rates of 30% IOP reduction are 23.5% for maximum 24-hour IOP and 11.8% for mean 24-hour IOP. When a topical combination therapy is needed to achieve the target reduction in IOP, travoprost without BAK is a superior option because preservatives such as BAK can induce conjunctival inflammation and affect success rates for filtering surgery.…”

“…Netland et al 22 reported that travoprost is more effective in blacks than nonblacks, so patient race might influence this result. Furthermore, Suh et al 17 reported the effect of travoprost 0.004% during 12 months of treatment and noted that IOP reduction was evident at one month; however, a slight increase in IOP occurred between nine and 12 months. Almost all of our data were obtained within a one-to twomonth period after the beginning of travoprost treatment, whereas the data from the study by Ang et al were obtained at six months.…”

“…9,[14][15][16] However, only two reports have investigated the effect of travoprost on NTG. 17,18 Suh et al 17 reported the effect of travoprost on clinic IOP measurements in patients with NTG over a 12-month period, and Ang et al 18 reported the effect of travoprost on daytime IOP in NTG patients. Neither group measured changes in IOP overnight in NTG patients.…”